Compare Neurocrine Biosciences Inc (NBIX) vs Western Union Co (WU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Western Union Co — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Western Union Co trades at $6.95 (market cap $2.18B). The key difference: Neurocrine Biosciences Inc is far larger — about 7.2× Western Union Co's market cap, and Western Union Co pays a 13.43% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | WU | |
|---|---|---|
Market Cap | $15.77B | $2.18B |
Sector | Health | Technology |
52-Week High | $185.50 | $10.28 |
52-Week Low | $123.10 | $6.36 |
Enterprise Value | $15.78B | $2.09B |
Dividend Yield | — | 13.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Western Union (WU) trades at $7.00, down 2.51% on the day, reflecting a bearish technical trend and mixed earnings performance with recent quarterly misses. Valuation metrics appear attractive with a P/E of 5.65 and P/S of 0.55, but revenue has declined from $4.5B in 2022 to $4.05B in 2025. The company is pursuing a $200 million cost-saving plan by 2027 and expanding its retail footprint through partnerships like Total Wireless, while its pending acquisition of Intermex faces regulatory scrutiny.
The outlook is cautious due to declining revenue, integration risks from the Intermex deal, and a high dividend yield that some analysts view as unsustainable. Near-term catalysts include regulatory approvals for the acquisition and execution of cost-cutting initiatives, but competitive pressures and margin compression pose significant risks to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →
